Disease relapse remains the major clinical challenge in treating T cell acute lymphoblastic leukemia (T-ALL), particularly those with PTEN loss. We hypothesized that leukemia-initiating cells (LICs) are responsible for T-ALL development and treatment relapse. In this study, we used a genetically engineered mouse model of Pten -/-T-ALL with defined blast and LIC-
Introduction
T cell acute lymphoblastic leukemia (T-ALL) is a common hematological malignancy that is associated with a significant risk of disease relapse and poor prognosis (1) . Activating mutations in NOTCH1 are present in approximately half of T cell leukemia patients (2) , and deletion or mutations of the PTEN tumor suppressor gene have been reported in 8-63% of pediatric T-ALL patients (3) (4) (5) (6) and are correlated with poor prognosis (7, 8) . Furthermore, PTEN is frequently inactivated non-genetically in primary T-ALL cells (9) and constitutive activation of the NOTCH signaling pathway down-regulates PTEN expression (6, 10) , suggesting that PTEN and its controlled PI3K/AKT/mTOR pathway are critical for the etiology of human T-ALL.
Individual cells within tumor masses exhibit notable heterogeneity in their functional and pathological properties. Recent evidence supports the model that the growth of many types of cancers, including leukemia, is sustained by a subset of cells, termed cancer stem cells (CSCs), that are responsible for the initiation and propagation of the disease and show ability to initiate cancer in xenografts or genetically engineered mouse models (11) (12) (13) (14) . CSCs are characterized by their self-renewal capacity and ability to generate all cell types that comprise the cancer, and are functionally distinct from the bulk of tumor cells that lack the ability to initiate tumor growth.
A consequence of this model is that therapies that only eliminate the bulk of the tumor cells without targeting CSCs will result in re-emergence of disease (15) .
In hematopoietic malignancies, frequent relapse following conventional chemotherapies suggests that leukemia-initiating cells (LICs) are spared by the treatment, which may be attributed to properties shared with normal hematopoietic stem cells such as maintenance of a quiescent state (16) (17) (18) . In acute myelogenous leukemia (AML), most LICs isolated from patient samples are quiescent (18) and protected from chemotherapeutic agents (19, 20) . Maintenance of a quiescent state has also been associated with LICs in chronic myelogenous leukemia (CML) and resistance to tyrosine kinase inhibitors (21, 22) . However, the identity and cell cycle status of LICs in T-ALL has not been explored to date. In order to understand the cellular and molecular basis of T-ALL relapse and develop more effective therapies, there is a need to characterize T-ALL LICs using functional assays and determine the relationship between LICs and disease relapse in models that mimic human T-ALL pathogenesis.
We previously generated a VE-Cadherin-Cre The difference between experimental groups was compared using Student's t test analysis.
Materials and Methods

Mice and transplantation assays
Survival in animal experiments was represented with Kaplan-Meier plots (Graphpad Prism).
IC50 was calculated using Graphpad Prism.
Supplementary Data
Supplementary data includes Supplementary materials and methods, seven Supplementary figures, and one Supplementary Table.
Results
Leukemia-Initiating Cells are Responsible for Therapeutic Resistance in Pten null T-ALL
We previously found that rapamycin, a specific TORC1 inhibitor, abrogated LIC formation by preventing the Tcrα/δ-c-Myc translocation, a critical secondary event for Pten null T-ALL development in this model (24) . However, when treatment began at the acute T-ALL stage, rapamycin extended survival but all Pten null animals eventually succumbed to T-ALL (24) . To understand the cellular and molecular mechanisms underlying relapse, we treated Pten null T-ALL mice with rapamycin for 7 days, harvested bone marrow cells, and transplanted these cells into secondary and tertiary NOD-SCID-IL2Rγ-/-(NSG) recipients in the absence of drug. We then retreated the transplant recipients with rapamycin to test whether rapamycin-treated T-ALL remained sensitive to the drug or acquired resistance mutations (Fig. 1A) . Rapamycin significantly reduced the percentage of phospho-S6 + cells, a surrogate marker for mTOR activity, in secondary and tertiary recipients from greater than 70% to 15% after 2 days of retreatment, suggesting that the majority of T-ALL cells remained sensitive to rapamycin (Fig. 1B ).
In addition, we did not detect "hotspot" mutations in Notch1 or Fbxw7, common alterations found in human T-ALL, after treatment (Fig. 1C) . Importantly only LICs, not blasts, harvested from tertiary re-treated animals could efficiently initiate T-ALL upon transplantation (Fig. 1D) . Altogether these data suggest that resistance to rapamycin is due to failure to eliminate LICs and not mutations in the mTOR or NOTCH pathways.
Co-targeting Deregulated PI3K and Myc Efficiently Eliminates Pten null LICs
The deregulated c-Myc oncogene, either via Tcrα/δ-c-Myc translocation or through its overexpression, is essential for LIC formation and leukemia development in the Pten null T-ALL model (24) and associated with LICs in NOTCH1-induced T-ALL (25) . Therefore we hypothesized that combination therapy that co-targets the PI3K pathway and deregulated c-Myc To test whether JQ1 can be used in combination with rapamycin for therapeutic utility, we transplanted leukemic cells from primary Pten null T-ALL into NSG recipients to generate a cohort of Pten null T-ALL animals to perform parallel analyses of treatment with agents, alone or in combination ( Supplementary Fig. S1A (23, 24) in the untreated and treated animals.
Phospho-S6 levels in blasts were significantly decreased after 7 days of rapamycin treatment in vivo, demonstrating inhibition of mTOR by rapamycin in this compartment ( Supplementary Fig.   S1B ). JQ1 significantly enhanced the effects of rapamycin in reducing splenomegaly and almost completely eliminated leukemic blasts after 7 days of daily in vivo treatment ( Fig. 2A ; left two panels). Importantly, the percentage of LICs in the bone marrow was markedly reduced with the combination treatment ( Fig. 2A; Fig. S1A ). While all animals receiving a 10 3 cell dose of rapamycin treated cells succumbed to T-ALL by approximately 30 days, none of the animals receiving the same dose of dual treated cells developed any sign of illness over more than 100 days (Fig. 2B ) and no leukemia cells could be detected in the euthanized animals using sensitive genomic PCR analysis ( Supplementary Fig. S1C ). Our regression analysis showed that combination treatment reduced the frequency of the LIC to ~1/200,000 ( Fig. 2C ), indicating that eliminating LIC number and activity are directly associated with this remarkable therapeutic response.
T-ALL May be Stratified and Treated According to its Molecular and Genetic Defects
The robust response of our Pten null T-ALL model to combination treatment of rapamycin and JQ1 prompted us to investigate the molecular mechanisms underlying T-ALL elimination and to test whether similar combination treatment can be applied to human T-ALL. For this, we generated a Pten null T-ALL in vitro culture system to circumvent the limitation of the in vivo 
LICs and Leukemic Blasts are Biologically Distinct and Respond Differently to Targeted Therapies
The remarkable responses of blast and LIC populations to rapamycin and JQ1 combination treatment in Pten null T-ALL in vivo prompted us to examine the specific effects of these agents in these distinct compartments. We hypothesized that the failure of rapamycin as a single agent to eliminate Pten null LICs in vivo may be due to the differential cellular and biochemical responses of LICs and blasts to rapamycin. Indeed, we found that a 2-day treatment with rapamycin in vivo greatly reduced levels of phospho-S6 in the blast cell compartment while levels of phospho-S6 remained high in LICs (Fig. 4A) . Furthermore, we found that Pten null LICs are markedly less sensitive to the effects of rapamycin on reducing cell size and nutrient receptor levels in comparison to blast cells (Fig. 4B) . These data suggest that failure to inhibit mTOR and effectively down-regulate nutrient receptors in the LIC compartment may underlie the mechanism of rapamycin resistance.
Because Myc is associated with LIC activity in both our model and NOTCH1-driven T-ALL, we evaluated the effect of JQ1 on Myc levels in the blasts and LIC-enriched compartments. While JQ1 reduced levels of c-Myc in both blast and LIC populations, we found that LICs are significantly more sensitive to JQ1-mediated down-regulation of c-Myc than their blast progenies ( Fig. 4C; 18% vs. 49% c-Myc + in LICs and blasts, respectively, after 500 nM JQ1 treatment).
Quantitative analysis revealed that LICs show 2-3 fold greater reduction in c-Myc levels after JQ1 treatment compared to blast cells (Fig. 4D) . The enhanced sensitivity of Pten null LICs to c-Myc down-regulation by JQ1 may be particularly valuable to efficiently target aberrant c-Myc levels in Pten null LICs and eliminate these cells. Taken together, these data demonstrate that LIC and blast subpopulations are not only functionally distinct but respond differently to targeted treatments.
LICs in Pten null T-ALL Are Actively Cycling
The proto-oncogene c-Myc is a key regulator of cell growth and cell cycle progression (35).
Since Pten null LICs over-express c-Myc, we evaluated the cell cycle status of LICs.
Intriguingly, when we measured BrdU incorporation in the bone marrow of primary and transplanted Pten null T-ALL in vivo, we found that a large portion of LICs were actively cycling (~50% BrdU + after 1 hour pulse labeling) similar to blast cells ( Fig. 5A and quantified in 5B).
This observation contrasts with studies of LICs in other hematopoietic malignancies, including AML and CML, in which the LICs reside mostly in a quiescent state (13, 19, 21) , however is similar to the increased levels of proliferation and self-renewal reported for Nras G12D mutant hematopoietic stem cells (36,37).
Our cell cycle analysis suggests that deregulated Myc expression in T-ALL LICs may promote their cell cycle entry and progression, which distinguishes T-ALL LICs from AML and CML LICs.
Consistent with this notion, we found that 86% of cells with high c-Myc levels (Myc high ) are also BrdU + while only 33% of cells with low c-Myc levels (Myc low ) cells are BrdU + (Fig. 5C ).
Importantly, JQ1 treatment could effectively eliminate the Myc high population (Fig. 5D ), supporting the idea that high c-Myc levels in the LIC subpopulation may drive LIC entry into the cell cycle. These unique characteristics of Pten null T-ALL LICs may render them sensitive to cell cycle inhibitors.
Pten null T-ALL LICs Can Be Effectively Eliminated by Aurora Kinase Inhibition in Combination with Rapamycin
Myc upregulation of Aurora kinases, which have essential roles in many aspects of cell division (38,39), is reported to be essential for the maintenance of Myc-driven malignancies (40).
Interestingly, we found that JQ1-induced c-Myc down-regulation is associated with a significant reduction of Aurora B levels (Fig. 6A) , suggesting that c-Myc regulates Aurora B in Pten null T-ALL. This node may be critical for leukemia maintenance and further implicates potential utility of cell cycle inhibitors to eradicate LICs.
In support of this hypothesis, the Aurora kinase inhibitor VX-680 has been reported to show synthetic lethality with Myc overexpression (41,42). Given the effects of JQ1 in reducing c-Myc and Aurora B levels in Pten null T-ALL, we were prompted to evaluate the effects of VX-680 in combination with rapamycin on Pten null T-ALL in vivo to further delineate the effects of antiMyc therapy to eliminate Pten null LICs. We treated a cohort of transplanted Pten null T-ALL mice with VX-680 and rapamycin, alone and in combination, and found that combination treatment caused nearly complete elimination of leukemia burden and a robust reduction in the LIC population (Fig. 6B) . Functional studies for LIC activity using transplantation of treated bone marrow into secondary NSG recipients showed again that dual treatment significantly reduced LIC activity in bone marrow compared to single agent alone ( Fig. 6C and 6D ). Limiting dilution analysis estimated that combination treatment reduced the frequency of the LIC to ~1/60,000, similar to but less potent than the JQ1 and rapamycin combination (Fig. 6C and 6D ).
These data suggest that an essential role of the deregulated Myc pathway in Pten null T-ALL LICs is regulating cell cycle progression and such a property can be targeted directly by JQ1 or indirectly with cell cycle inhibitors.
VX-680 causes Mitotic Block, Polyploidy, and Apoptosis in Pten null T-ALL
We used our in vitro model to evaluate the cellular and biochemical effects of VX-680 on Pten null T-ALL and determine potential mechanisms underlying T-ALL elimination. Pten null T-ALL cells were highly sensitive to VX-680 (IC50 ~83 nM) and treatment decreased levels of phosphorylation of Histone H3 at Ser10, a surrogate for Aurora B kinase activity, within 8 hours (Fig. 7A) . We further tested the sensitivity of several human PTEN null T-ALL lines to VX-680. Fig. 7C-E) .
We also detected increased levels of phosphorylated H2AX and induction of p53 and p21 in Pten null T-ALL, suggesting the p53 pathway may be involved in the DNA damage response and subsequent apoptosis (Fig. 7E) . Although VX-680 causes mitotic block and polyploidy in Jurkat cells, it does not induce apoptosis as illustrated by the lack of a sub-G1 population and absence of cleaved PARP and caspase 3 ( Fig. 7C-E) , possibly due to the presence of a p53 mutation. These results suggest that therapeutic approaches using VX-680 may be most effective in human T-ALL with PTEN loss, functional p53, and genetic or molecularly deregulated Myc. Clinical data suggests that conventional chemotherapies may reduce the "bulk" of the leukemia (blast cells), but fail to eradicate the LICs, leading to relapse (15) . In this study, our Pten null T-ALL model with functionally defined and distinguishable blast and LIC-enriched populations provides a valuable platform to develop novel targeted molecular therapies in which efficacy can be evaluated in both LICs and the bulk of the disease. Our biochemical and molecular analysis of drug effects on the blast and LIC-enriched compartments revealed that LICs and blasts show remarkably distinct responses to targeted therapies. While the bulk of Pten null T-ALL shows rapid and robust inhibition of the mTOR pathway by rapamycin, even after multiple rounds of therapy, rapamycin fails to inhibit mTOR and down-regulate nutrient receptor expression in the LIC compartment, which retains LIC activity after treatment. These data suggest that relapse of Pten null T-ALL in response to rapamycin is caused by the failure to eliminate LICs. While many studies have provided evidence that LICs in AML and CML reside in a quiescent state (13, 19, 21) , to our knowledge the cell cycle status of LICs in T-ALL has thus far never been characterized. We demonstrated that a large portion of LICs in T-ALL are actively cycling and hypothesized that deregulated Myc is responsible for promoting cell cycle entry and progression of T-ALL LICs. We found JQ1 preferentially targets cells that have high Myc levels and are actively cycling. Importantly, the active cycling nature of T-ALL LICs suggests that cell cycle inhibitors may be useful to target T-ALL LICs and offer therapeutic benefits to eliminate T-ALL.
Discussion
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Indeed, rapamycin in combination with the Aurora kinase inhibitor VX-680 effectively reduced
Pten null LICs and T-ALL in vivo. While we attribute the active cycling of Pten null LICs to deregulated Myc expression, it is possible that activation of other signaling pathways may also contribute to cycling. Notably, Nras G12D mutant hematopoietic stem cells have been recently reported to show increased proliferation and self-renewal (37).
Our study provides support that LICs are responsible for relapse and uncovers a role for anti-MYC directed therapies to target LICs, similar to a recent study (44). We also reveal a role for rapamycin as an effective agent to rapidly reduce the bulk of the leukemia, the blast population. The most effective anticancer regimens will likely involve combination approaches using therapies that kill both bulk tumor cells and disease-initiating cells (15) . Our novel combination treatment strategy using agents to target the PI3K pathway and deregulated Myc is consistent with this paradigm to provide anticancer therapies that quickly reduce disease burden and eliminate the root of the cancer. patient derived cell line, will further our understanding of patient response. Overall our study strongly suggests that human T-ALL needs to be stratified by the molecular genetic events associated with LIC formation and treated by co-targeting pathways of addiction.
Loss of PTEN and deregulation of
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